Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose pharmacokinetics of alitretinoin in moderate to severe hepatic impairment
2010-020212-11Phase 4Completed
- Sponsor
- Overlæge dr.med. Frederik Grønhøj
- Start
- Jul 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of alitretinoin in hepatic impairment (2 arms), sponsored by Overlæge dr.med. Frederik Grønhøj. Primary endpoints: Single-dose pharmacokinetics of alitretinoin and metabolites and Renal clearance of parent drug and metabolites. Started Jul 2010; status: completed.
02
Drugs
alitretinoin
03
Conditions
hepatic impairment
Beyond the preview
Go deeper on 2010-020212-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020212-11.